Aquestive Therapeutics (NASDAQ:AQST) Upgraded to Strong-Buy at Lifesci Capital

Key Points

• Lifesci Capital has upgraded Aquestive Therapeutics (NASDAQ:AQST) to a "strong-buy" rating, indicating a positive sentiment about the company's future performance.
• The stock has an average price target of $10.14 from various analysts, with one rating it as "Strong Buy", seven as "Buy", and one as "Hold".
• Despite recent challenges, Aquestive Therapeutics reported earnings that beat analyst estimates, with a loss of ($0.14) per share, improving from expectations of ($0.18).

Lifesci Capital upgraded shares of Aquestive Therapeutics (NASDAQ:AQST - Free Report) to a strong-buy rating in a research report report published on Wednesday morning,Zacks.com reports. Lifesci Capital also issued estimates for Aquestive Therapeutics' Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.65) EPS, Q1 2026 earnings at ($0.24) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.86) EPS.

Other analysts have also recently issued research reports about the company. Oppenheimer started coverage on Aquestive Therapeutics in a research report on Monday, June 2nd. They issued an "outperform" rating and a $7.00 price target for the company. Zacks Research upgraded Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 13th. Finally, HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research note on Tuesday, June 17th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $10.29.

Aquestive Therapeutics Trading Down 7.6%

NASDAQ AQST traded down $0.41 on Wednesday, hitting $5.01. 3,305,338 shares of the stock traded hands, compared to its average volume of 1,621,092. The stock has a 50-day moving average of $3.98 and a 200 day moving average of $3.25. The company has a market capitalization of $499.60 million, a P/E ratio of -7.16 and a beta of 1.82. Aquestive Therapeutics has a twelve month low of $2.12 and a twelve month high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.04. The business had revenue of $10.00 million during the quarter, compared to the consensus estimate of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Aquestive Therapeutics

Several institutional investors have recently made changes to their positions in AQST. BNP Paribas Financial Markets lifted its stake in Aquestive Therapeutics by 78.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company's stock valued at $31,000 after purchasing an additional 4,134 shares during the last quarter. Summit Wealth & Retirement Planning Inc. bought a new stake in Aquestive Therapeutics during the first quarter valued at $29,000. USAdvisors Wealth Management LLC bought a new position in shares of Aquestive Therapeutics during the 2nd quarter worth about $33,000. Modern Wealth Management LLC bought a new position in shares of Aquestive Therapeutics during the 2nd quarter worth about $33,000. Finally, Victory Capital Management Inc. bought a new position in shares of Aquestive Therapeutics during the 1st quarter worth about $31,000. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.